J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pham, D. Q.
Right arrow Articles by Chu, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pham, D. Q.
Right arrow Articles by Chu, V.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

THERAPEUTIC REVIEW

Inhaled Human [rDNA Origin] Insulin, a Novel Formulation for Diabetes Mellitus

David Q. Pham, PharmD, Henry Cohen, PharmD, FCCM and Valery Chu, PharmD

From the Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York (Dr Pham, Dr Cohen); Kings County Hospital Center, Brooklyn, New York (Dr Pham); and Kingsbrook Jewish Medical Center, Brooklyn, New York (Dr Cohen, Dr Chu).

Diabetic complications have been reduced significantly with the introduction of insulin more than 8 decades prior. Despite the proven benefits of normal glycemic levels, patients are deterred by the inconvenience and expect worse pain than there is on average with multiple daily insulin injections. Inhaled insulin was approved by the Food and Drug Administration in early 2006 and is a novel product that introduces inhaled insulin as an alternate to the traditional subcutaneous delivery system, and hence could potentially improve patient compliance. The objective of this article is to review the clinical pharmacology, pharmacokinetic and pharmacodynamic properties, clinical efficacy, and tolerability of inhaled insulin.

Key Words: Inhaled insulin • Exubera • clinical trials • efficacy • adverse effects

Address for correspondence: David Q. Pham, PharmD, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Division of Pharmacy Practice, 75 DeKalb Avenue, Brooklyn, NY 11201-5497; e-mail: david.pham{at}liu.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology